Steven Cohen’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,222,213
Closed -$38.8M 4462
2025
Q4
$38.8M Sell
1,222,213
-84,485
-6% -$2.54M 0.04% 521
2025
Q3
$30.7M Buy
+1,306,698
New +$22.4M 0.05% 399
2024
Q2
Sell
-142,458
Closed -$1.92M 2419
2024
Q1
$1.92M Buy
+142,458
New +$863K ﹤0.01% 1277
2023
Q2
Sell
-9,409
Closed -$78.4K 2756
2023
Q1
$78.4K Sell
9,409
-19,291
-67% -$174K ﹤0.01% 1683
2022
Q4
$265K Buy
+28,700
New +$298K ﹤0.01% 1226
2022
Q1
Sell
-233,997
Closed -$5.61M 1383
2021
Q4
$5.61M Buy
+233,997
New +$5.58M 0.02% 642
2020
Q4
Sell
-39,244
Closed -$1.31M 1122
2020
Q3
$1.31M Buy
+39,244
New +$1.12M 0.01% 749

Other funds holding STOK

Steven Cohen's STOK Position: Q1 2026 in Review

Steven Cohen sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 1,222,213 shares — an estimated $38.8M sold.

Steven Cohen first reported a position in STOK in Q3 2020 and held it in 7 quarters. The position peaked at $38.8M in Q4 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Steven Cohen reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Steven Cohen sold 1,222,213 Stoke Therapeutics shares in Q1 2026, an estimated $38.8M.
  • Steven Cohen first reported a position in Stoke Therapeutics in Q3 2020 and held it in 7 quarters.
  • Steven Cohen's Stoke Therapeutics position peaked at $38.8M in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.